Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Gets Two Patents for Protein Profiling Technology

NEW YORK, June 26 - Ciphergen said today it has been awarded two patents for its SELDI protein profiling technology.


The patents include European Patent EP 0 700 521 B1, which covers the devices, methods, and instruments of SELDI, or Surface Enhanced Laser Desorption, technology, and US Patent 6,579,719, which covers protein expression profiling using chromatographic surfaces and detecting them with laser desorption mass spectrometry.


Ciphergen has exclusively licensed the first patent from Baylor College of Medicine, and is the sole owner of the US Patent.


"The European patent secures our rights to our core SELDI technology in Europe, and the U.S. patent supplements our basic U.S. patents with coverage for the most important ProteinChip technology application -- protein expression profiling -- which is at the heart of protein biomarker discovery," William Rich, President and CEO of Ciphergen, said in a statement.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.